Regenerative Medicine Partnership Focused on Development of Novel Stem Cell Therapy CLEVELAND and TOKYO, March 2, 2015 -- Athersys, Inc. and Chugai Pharmaceutical Co., Ltd. have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Ischemic stroke represents a priority disease area in Japan, given the high healthcare burden of the condition and the expected increase in incidence associated with Japan's aging population.
http://ift.tt/1vROmKH
http://ift.tt/1vROmKH
No comments:
Post a Comment